Preemptive use of etodolac on tooth sensitivity after in-office bleaching: a randomized clinical trial
Introduction
Tooth whitening is a simple and non-invasive treatment commonly carried out to reestablish smile aesthetics. High success rates have been demonstrated for bleaching techniques applying 35% hydrogen peroxide (HP35%) 2 . Hydrogen peroxide (H 2 O 2 )-based bleaching agents at high concentrations (typically 15-38%) are currently used for in-office techniques due to their high oxidizing ability 12, 25 . However, the low molecular weight of H 2 O 2 allows its penetration across the entire dentin tissue, reaching the pulp chamber and promoting damage of pulp stem cells, which is reported by patients as tooth sensitivity 15, 29 .
Prior clinical trials have reported absolute risk of tooth sensitivity as high as 95% when highly concentrated H 2 O 2 is used for in-office tooth bleaching 9, 20, 23, 25 . Thus, the preemptive use of desensitizer agents 3, 30 or antiinflammatories 7, 22, 23, 27 has been proposed to reduce the risk of post-bleaching tooth sensitivity. Only the former significantly decreased tooth sensitivity; however, the application of desensitizers, when not incorporated into the bleaching gel, adds an extra step to the bleaching protocol, which is contrary to a clinician's need for simplification. On the other hand, the preemptive use of anti-inflammatories does not increase the number of steps in the bleaching protocol. Unfortunately, prior studies evaluating etoricoxib, ibuprofen, or
dexamethasone were unable to demonstrate any beneficial effect on tooth sensitivity caused by tooth bleaching 7, 13, 22, 23, 28 .
Etoricoxib and ibuprofen are grouped as class II drugs by the Biopharmaceutical Classification
System (BCS), presenting low solubility and high permeability, which can hinder their absorption and create bioavailability mismatch during the bleaching procedure
28
. Moreover, anti-inflammatory drugs may have a specific action over inflammatory mediators (bradykinin) and the neurotransmitter (substance P) of tooth pain caused by dental bleaching Thus, this study aimed to evaluate the effectiveness of the preemptive prescription of etodolac on risk of tooth sensitivity during and after in-office bleaching treatment. The first hypothesis evaluated was that etodolac would reduce both level and risk of tooth sensitivity when administrated in a single dose prior to in-office bleaching. The second hypothesis tested was whether the use of etodolac would reduce tooth sensitivity with no effect on tooth bleaching.
Material and methods
This clinical trial followed the CONSORT 
Sample size calculation
The sample calculation was based on the primary binary outcome (sensitivity risk 24 hours after the procedure) for superiority trial. The power of the test was set at 80%, considering a type I error of 0.05 and risk of tooth sensitivity of 90%, based on a prior study using a similar bleaching agent 23 ; moreover, a reduction around 30% was expected after treatment.
The calculation resulted in fifty patients.
Randomization
A randomized list was computer-generated by a person not involved in intervention or evaluation.
Participants were defined as blocks in the randomization process, in which the sequence of treatment (placebo or etodolac) was randomly set for each block by computer-generated tables (www.sealedenvelope. mild; 2= moderate; 3= considerable; and 4= severe.
Tooth sensitivity was assessed during bleaching, immediately after removing the bleaching agent, and after 24 hours. For this last assessment, only the VRS was used due to the difficulty of patients to fill the VAS at home. One week after each session, tooth color was evaluated again using the same procedure described previously. There was no difference among the sequences of treatment for any demographic characteristic analyzed (age: p=0.089 and gender: p=0.140). Table 2 shows the results of tooth sensitivity risk.
The treatment that patients received prior to the bleaching procedure did not affect the risk to sensitivity at any of the moments of evaluation (during and immediately after: p=1.0; after 24 hours: p=0.683). preemptive administration of anti-inflammatories could be a reasonable approach to reduce tooth sensitivity associated with bleaching procedures. However, in this study, sensitivity was not lower during and 24 hours after the bleaching procedure. Unfortunately, the peak of tooth sensitivity was not measured in this study, even though this outcome could allow to assess a possible effect of etodolac on sensitivity following the end of the bleaching procedure.
A prior study demonstrated that etodolac presents higher effectiveness on bradykinin inhibition than other drugs commonly used to control the inflammatory process, motivating its use in this study 18 . Regarding pharmacokinetics, etodolac reaches its maximal plasma concentration around 1 to 2 hours after its Another important observation regarding pharmacokinetics is that a crossover design was used in this study with a 1-week interval period. Considering that the half-life of etodolac after oral administration is around 13 hours 16 , it is expected to find no residual effect after 1-week. Moreover, the crossover design avoids bias related to pain thresholds of patients In our study, the protocol that was carried out resulted in significant bleaching effect, while an additional color alteration was achieved at the second session. In addition, the last color evaluation was performed a week after the last bleaching session of this study, while longer times may be required . We found no difference in baseline regarding these parameters between the sequence of allocation, while the inclusion of young participants presenting all teeth darker than 2.5 M2
(score 7) favored obtaining significant color bleaching.
In conclusion, the preemptive administration of 
Conclusions
The preemptive administration of a single dose of etodolac previously to the two bleaching sessions with 35% hydrogen peroxide did not affect tooth color change, risk of sensitivity and level of pain reported by the patients (during the sessions, immediately after, and 24 h after sessions).
